[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 21, Issue 4 (10-2013) ::
Journal of Ilam University of Medical Sciences 2013, 21(4): 171-190 Back to browse issues page
Overview of Cyclic Nucleotide Phosphodiesterase Isoenzyme: a Review Article
M Saberi karimian , M Parizad , S Samadi , D Alamdari , D Mosavi nasab , N Ahmadi * 1, M Hadavi
1- , nayebalia@sbmu.ac.ir
Abstract:   (29001 Views)
Phosphodiesterase enzymes (PDEs) cata-lyze selectively the hydrolysis of the cAMP and cGMP cyclic nucleotides. Nowadays, 53 isoenzymes have been identified in 11 families of Phosphodiesterase enzymes. The enzymes control the accesibilty of sec-ond messengers to their intracellular effectors. PDEs display variation in struct-ure, kinetic characteristics, regulatory mec-hanisemes, inhibitor sensivity, and response to special factors as well as the affinity to substrate (cAMP and cGMP). Each PDE family not only have their own specific sub-strates and regulatory characteristics, but also display their own specific tissue, cellu-lar and subcellular expression patterns and consequently participate in different signal transduction pathways. The importance of physiological effects of cAMP and PDE inhibitors was clarified in 1950s. The cAMP nucleotide was introdu-ced as a second messenger that mediating many cellular impacts of nourological tran-smitters and hormones. The second messen-ger, cGMP, was discovered a few years later in rat urine. Recent studies have dem-onstrated that phosphodiesterase enzymes can be inhibited nonselectively by IBMX (3-isobutyl-1-methyl-xantine) which increa-seng cAMP level and the IC50 for all PDEs were reported o be in the range of milim-olar, with the exception for PDE8A, PDE8-B and PDE9A. Obviously, the clinical usage of different PDE inhibitors has been known in recent years. Among various PDE inhibitors some compounds were not acceptable for the sake of their undesirable side effects. Overlap ping enzyme activity, drug sensivity and tissue distribution of phosphodiesterases comprised their side effects. Further invest-ingation of PDEs in order to identifiy new PDE inhibitors would lead to improve their therapeutic effects and reduce their undesir-able side effects.
Keywords: cyclic nucleotide phosphodiesterase, phosphodiesterase inhibitors
Full-Text [PDF 679 kb]   (8717 Downloads)    
Type of Study: Research | Subject: Internal operations( nursing )
Received: 2013/10/14 | Accepted: 2013/10/15 | Published: 2013/10/15
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

saberi karimian M, parizad M, samadi S, alamdari D, mosavi nasab D, ahmadi N et al . Overview of Cyclic Nucleotide Phosphodiesterase Isoenzyme: a Review Article . J. Ilam Uni. Med. Sci. 2013; 21 (4) :171-190
URL: http://sjimu.medilam.ac.ir/article-1-1268-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 4 (10-2013) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4653